TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20515208

Group type: EXPERIMENTAL
Intervention: TAU plus CBT-GSH
Number of subjects: 123

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 123
Study: 18448601

Group type: EXPERIMENTAL
Intervention: Telehealth delivery of the Lidcombe Program of Early Stuttering Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 0
Study: 16416357

Group type: EXPERIMENTAL
Intervention: Lead exposure (mean PbB 5.4 microg Pb/100 ml)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (mean PbB 4.7 microg Pb/100 ml)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High cumulative lead exposure (IBL, >5000; duration of exposure, >5 years)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Lead exposure (current and cumulative measurements)
Number of subjects: 48
Study: 12391100

Group type: EXPERIMENTAL
Intervention: (13)C‐enriched 6% CHO(exo) beverage (total volume per trial: 24 ml/kg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: (13)C‐enriched 6% CHO(exo) beverage
Number of subjects: 22
Study: 10571596

Group type: EXPERIMENTAL
Intervention: Oral plus topical mesalazine (2.4 g/day oral + 4 g/day topical)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Oral mesalazine (2.4 g/day)
Number of subjects: 22
Study: 8687366

Group type: EXPERIMENTAL
Intervention: Exposure in vivo (group treatment)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cognitive therapy followed by exposure in vivo (group treatment)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural treatment (integrated from the start, group treatment)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Individual treatments
Number of subjects: 50
Study: 2065622

Group type: EXPERIMENTAL
Intervention: Ascorbic Acid (AA) solution
Number of subjects: 60
Study: 7027746

Group type: EXPERIMENTAL
Intervention: Metoprolol, 100 mg b.i.d.
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 29669780

Group type: EXPERIMENTAL
Intervention: Torsional phacoemulsification with adjunctive endocapsular nuclear fragmentation using a manual microinterventional nitinol filament loop device (miLOOP)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Torsional phacoemulsification alone (controls)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Torsional phacoemulsification with miLOOP
Number of subjects: 101
Study: 28728606

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (1200 mg/day)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Celecoxib (200 mg/day)
Number of subjects: 119
Study: 24860124

Group type: EXPERIMENTAL
Intervention: 4% succinylated gelatin (Gelofusine, GEL group, n = 40)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 1‐2 units FFP (FFP group, n = 40)
Number of subjects: 80
Study: 23832729

Group type: EXPERIMENTAL
Intervention: Two cans per day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Three cans per day
Number of subjects: 27
Study: 16955450

Group type: EXPERIMENTAL
Intervention: Case 1a (female patient with mild cognitive impairment)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Case 1b (male patient with mild cognitive impairment)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Case 2a (vascular dementia)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Case 2b (Alzheimer's disease)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Follow-up interest in geriatric (psychiatric) topics
Number of subjects: 122
Study: 14986193

Group type: EXPERIMENTAL
Intervention: Active recovery
Number of subjects: 15
Study: 11672492

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural intervention (4 sessions)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural intervention (2 sessions)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Self-help booklet (control condition)
Number of subjects: 64
Study: 9423999

Group type: EXPERIMENTAL
Intervention: Single 10 Gy treatment
Number of subjects: 280

Group type: COMPARATOR
Intervention: 22.5 Gy in five daily fractions
Number of subjects: 280
Study: 8237259

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg bid
Number of subjects: 394
Study: 3541803

Group type: EXPERIMENTAL
Intervention: D + M (400 mg of doxycycline + 1500 mg of metronidazole)
Number of subjects: 261

Group type: COMPARATOR
Intervention: D (400 mg of doxycycline)
Number of subjects: 261
Study: 11388526

Group type: EXPERIMENTAL
Intervention: Ropivacaine 10 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ropivacaine 20 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ropivacaine 30 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ropivacaine 40 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ropivacaine 50 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Ropivacaine (various doses)
Number of subjects: 66
Study: 30643223

Group type: EXPERIMENTAL
Intervention: Texture-modified foods and thickened drinks diet (nectar or pudding viscosity, controlled bolus volume) for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isocaloric standard treatment for 12 weeks
Number of subjects: 40
Study: 29480843

Group type: EXPERIMENTAL
Intervention: Early rehabilitation therapy
Number of subjects: 86

Group type: COMPARATOR
Intervention: Routine primary therapy (Control)
Number of subjects: 86
Study: 26878772

Group type: EXPERIMENTAL
Intervention: specific amino acid mixture with micronutrients
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: psychological neurological questionnaire (PNF)
Number of subjects: 32
Study: 24465570

Group type: EXPERIMENTAL
Intervention: PHiD-CV (10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine)
Number of subjects: 600
Study: 22228773

Group type: EXPERIMENTAL
Intervention: fenofibrate/pravastatin 160/40 mg plus ezetimibe 10 mg (triple therapy)
Number of subjects: 273

Group type: COMPARATOR
Intervention: simvastatin 20 mg plus ezetimibe 10 mg (dual therapy)
Number of subjects: 273
Study: 20435707

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 249
Study: 17688170

Group type: EXPERIMENTAL
Intervention: Sodium salicylate iontophoresis
Number of subjects: 20

Group type: COMPARATOR
Intervention: TENS
Number of subjects: 20
Study: 16276320

Group type: EXPERIMENTAL
Intervention: Soft disposable contact lenses (SCL), Biomedics 55 2-week disposable lenses, worn during waking hours.
Number of subjects: 81

Group type: COMPARATOR
Intervention: Overnight corneal reshaping (OCR), CRT lenses by Paragon, worn only while sleeping.
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Preference after both phases of the study.
Number of subjects: 81
Study: 12107720

Group type: EXPERIMENTAL
Intervention: Insulin infusion (1 mU/kg per min for 60 min) during adenosine infusion (140 microg/kg per min i.v.)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Adenosine infusion (140 microg/kg per min i.v.) without insulin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Normoglycaemia (plasma glucose 6 mmol/l)
Number of subjects: 19
Study: 10430967

Group type: EXPERIMENTAL
Intervention: Hemodialysis patients on a controlled low-nitrate diet (approximately 330 micromol/d) for 48 hours.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy subjects (control group).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemodialysis patients with elevated plasma levels of citrulline and asymmetric dimethylarginine (ADMA).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemodialysis patients receiving antihypertensive therapy.
Number of subjects: 0
Study: 8699846

Group type: EXPERIMENTAL
Intervention: Pentoxifylline 1,200 mg daily for 2 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2347957

Group type: EXPERIMENTAL
Intervention: Aspartame (15 mg/kg body weight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 10
Study: 379366

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy with tetracycline
Number of subjects: 50

Group type: COMPARATOR
Intervention: Chlamydia trachomatis infection
Number of subjects: 50

Group type: COMPARATOR
Intervention: Chlamydia trachomatis infection in female partners
Number of subjects: 50
Study: 31699723

Group type: EXPERIMENTAL
Intervention: Modified nutrition group (increased vegetable and fruit, reduced dairy milk)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Modified nutrition group (lycopene supplementation)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Physical activity group (brisk walking)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (nutrition)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (physical activity)
Number of subjects: 81
Study: 28570250

Group type: EXPERIMENTAL
Intervention: NPWTi with 0.125% sodium hypochlorite solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: NPWT without instillation
Number of subjects: 20
Study: 26267728

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient's Self-Assessment (PSA) scale
Number of subjects: 0
Study: 23347472

Group type: EXPERIMENTAL
Intervention: Cognitive inhibition assessed with the Color‐Word Interference Test (D‐KEFS)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Heart rate variability (HRV) measured using high frequency (HF) power (ms(2))
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control for depression
Number of subjects: 36
Study: 21316788

Group type: EXPERIMENTAL
Intervention: Structured behavioural intervention to increase physical activity
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study: 19746242

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 86

Group type: COMPARATOR
Intervention: Nonspironolactone (Control)
Number of subjects: 86
Study: 17825710

Group type: EXPERIMENTAL
Intervention: ST-segment elevation criteria
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: ST-segment elevation and depression criteria
Number of subjects: 116
Study: 15505095

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control group (ICD activated, CRT off)
Number of subjects: 186
Study: 11488132

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine 1:80,000
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 3% mepivacaine with epinephrine 1:100,000
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 3% mepivacaine with no associated vasoconstrictor
Number of subjects: 43
Study: 10422491

Group type: EXPERIMENTAL
Intervention: pravastatin Lipostat 20
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: phenofibrate Lipanthyl 200M
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: simvastatin Zocor 20
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: no hypolipemic medication
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no accelerated atherosclerosis)
Number of subjects: 89
Study: 7999482

Group type: EXPERIMENTAL
Intervention: Continuous i.v. infusion (group A: 1.25 u.h‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Repeated i.v. boluses (10 u./2 h)
Number of subjects: 80
Study: 2897785

Group type: EXPERIMENTAL
Intervention: Somatostatin (SRIF) infusion (500 micrograms/h) for 90 min before and 5 h after a protein meal (240 g of meat)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 11
Study: 30277030

Group type: EXPERIMENTAL
Intervention: Counselor-initiated (CI) condition
Number of subjects: 248

Group type: COMPARATOR
Intervention: Self-paced (SP) condition
Number of subjects: 248
Study: 27121602

Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenge (DBPCFC)
Number of subjects: 1142

Group type: COMPARATOR
Intervention: Placebo day during DBPCFC
Number of subjects: 1142

Group type: EXPERIMENTAL
Intervention: DBPCFC with no severe immediate reactions
Number of subjects: 1142
Study: 26258613

Group type: EXPERIMENTAL
Intervention: Multivariate model compensation
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Multivariate model
Number of subjects: 202
Study: 23921906

Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test (FIT) outreach
Number of subjects: 6970

Group type: EXPERIMENTAL
Intervention: Colonoscopy outreach
Number of subjects: 6970

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6970

Group type: EXPERIMENTAL
Intervention: Comparison between FIT and Colonoscopy outreach
Number of subjects: 6970
Study: 21059836

Group type: EXPERIMENTAL
Intervention: Testosterone gel (5 g/d)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Testosterone gel (10 g/d)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: rhGH (3 μg/kg/d)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: rhGH (5 μg/kg/d)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Co-treatment with rhGH
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Changes in testosterone and insulin‐like growth factor 1 levels
Number of subjects: 112
Study: 18505564

Group type: EXPERIMENTAL
Intervention: Antidepressants (specific agents not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16616744

Group type: EXPERIMENTAL
Intervention: Preoperative measurement of IL‐6 by ELISA
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Preoperative measurement of TNF‐alpha by ELISA
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Preoperative measurement of IL‐8 by ELISA
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Preoperative measurement of E‐selectin by ELISA
Number of subjects: 50
Study: 14669258

Group type: EXPERIMENTAL
Intervention: Nigella sativa oil (black seed oil) at a dose of 40 to 80 mg/kg/day
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Nigella sativa oil (black seed oil)
Number of subjects: 152
Study: 11307093

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 65

Group type: COMPARATOR
Intervention: H-graft portacaval shunt
Number of subjects: 65
Study: 9085939

Group type: EXPERIMENTAL
Intervention: Group B (severe acute myocardial infarction)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nonsurvivors (n = 13)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Plasma IL-1 receptor antagonist and IL-10 levels
Number of subjects: 34
Study: 1493941

Group type: EXPERIMENTAL
Intervention: GM-CSF treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no GM-CSF treatment)
Number of subjects: 0
Study: 3159197

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 0
Study: 31943173

Group type: EXPERIMENTAL
Intervention: Book-based language intervention program
Number of subjects: 464
Study: 31375443

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 231
Study: 27890522

Group type: EXPERIMENTAL
Intervention: Tamsulosin (alpha-adrenergic blocker)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25539697

Group type: EXPERIMENTAL
Intervention: Deliberate practice (DP)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control training (educational videos or journal articles)
Number of subjects: 14
Study: 24187118

Group type: EXPERIMENTAL
Intervention: Home visiting program (9 visits over 3 years)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Control condition (no home visits)
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Home visiting program
Number of subjects: 302
Study: 21221815

Group type: EXPERIMENTAL
Intervention: Intergenerational volunteering intervention (hour-long volunteer sessions with kindergarten and older elementary classes over 5 months)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study: 19028148

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 110
Study: 17264337

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 6) and Paclitaxel (200 mg/m2 every 3 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Gemcitabine (1 g/m2 days 1 and 8) and Cisplatin (60 mg/m2 day 1 every 3 weeks)
Number of subjects: 100
Study: 12933419

Group type: EXPERIMENTAL
Intervention: IT fentanyl 25 micro g and hyperbaric bupivacaine 2.5 mg (Group H)
Number of subjects: 37

Group type: COMPARATOR
Intervention: IT fentanyl 25 micro g and plain bupivacaine 2.5 mg (Group P)
Number of subjects: 37
Study: 10407502

Group type: EXPERIMENTAL
Intervention: LDL-apheresis and drugs
Number of subjects: 36

Group type: COMPARATOR
Intervention: Drugs only (control group)
Number of subjects: 36
Study: 8888091

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 110

Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 110

Group type: COMPARATOR
Intervention: Rocuronium
Number of subjects: 110
Study: 1810257

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (1000 mg orally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6630599

Group type: EXPERIMENTAL
Intervention: Curettage and electrodesiccation once
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Curettage and electrodesiccation three times
Number of subjects: 0
Study: 3918495

Group type: EXPERIMENTAL
Intervention: Penicillin V (pcV)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 29024278

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor dapagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Loop diuretic bumetanide
Number of subjects: 0
Study: 27729061

Group type: EXPERIMENTAL
Intervention: Healthy Conversation Skills support plus vitamin D supplementation (1000 IU cholecalciferol)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Healthy Conversation Skills support plus placebo
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Usual care plus vitamin D supplementation (1000 IU cholecalciferol)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual care plus placebo
Number of subjects: 600
Study: 24473242

Group type: EXPERIMENTAL
Intervention: Post-stroke care with exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Post-stroke care without exercise
Number of subjects: 20
Study: 22458432

Group type: EXPERIMENTAL
Intervention: MVG technique
Number of subjects: 72

Group type: COMPARATOR
Intervention: Anatomic CTI ablation (unmatched)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Anatomic CTI ablation (matched)
Number of subjects: 72
Study: 20394544

Group type: EXPERIMENTAL
Intervention: Rubber tube
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Silicone tube
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 17967833

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 257
Study: 15680453

Group type: EXPERIMENTAL
Intervention: Early surgery (haematoma evacuation within 24 hours of randomisation)
Number of subjects: 1033

Group type: COMPARATOR
Intervention: Initial conservative treatment (medical treatment, with later evacuation allowed if necessary)
Number of subjects: 1033
Study: 12922086

Group type: EXPERIMENTAL
Intervention: New pediatric tick-borne encephalitis (TBE) vaccine
Number of subjects: 3559
Study: 10669065

Group type: EXPERIMENTAL
Intervention: Daily combination tablet administration (8 mg buprenorphine + 2 mg naloxone)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 8 mg alternate-day buprenorphine administration
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 16 mg alternate-day buprenorphine administration
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo on interposed day during alternate-day treatment
Number of subjects: 26
Study: 8797613

Group type: EXPERIMENTAL
Intervention: Low-dose anti-tumor necrosis factor therapy
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Anti-tumor necrosis factor therapy
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: High-dose anti-tumor necrosis factor therapy
Number of subjects: 553
Study: 1632683

Group type: EXPERIMENTAL
Intervention: Single donor-specific transfusion (DST) 24 to 48 hours before transplant with intravenous cyclosporine initiated after transfusion
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Multiple pretransplant DSTs with cyclosporine begun pretransplant
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Multiple pretransplant DSTs with cyclosporine begun after transplant
Number of subjects: 86
Study: 6208968

Group type: EXPERIMENTAL
Intervention: Preterm formula based on cows' milk
Number of subjects: 61

Group type: COMPARATOR
Intervention: Banked breast milk or maternal milk supplement
Number of subjects: 61
Study: 31567665

Group type: EXPERIMENTAL
Intervention: Adipose-Derived Cellular Bone Matrix (ACBM)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Autologous Bone Graft (Autograft)
Number of subjects: 140
Study: 29110305

Group type: EXPERIMENTAL
Intervention: Trees
Number of subjects: 50

Group type: COMPARATOR
Intervention: Playground equipment and sitting/eating areas
Number of subjects: 50
Study: 30641007

Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule (XFC), 0.5 g per pill, 3 pills each time, three times per day for 12 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sulfasalazine (SASP), 0.25 g per tablet, 4 tablets each time, twice per day for 12 weeks
Number of subjects: 76
Study: 24708675

Group type: EXPERIMENTAL
Intervention: Vancomycin trough level < 10 μg/mL
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Vancomycin trough level 10 μg/mL to < 15 μg/mL
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Vancomycin trough level ≥ 15 μg/mL
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Vancomycin trough level < 10 μg/mL (after excluding certain patients)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Vancomycin trough level 10 μg/mL to < 15 μg/mL (after excluding certain patients)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Vancomycin trough level ≥ 15 μg/mL (after excluding certain patients)
Number of subjects: 98
Study: 22124360

Group type: EXPERIMENTAL
Intervention: High-dose group (3700 MBq)
Number of subjects: 341

Group type: COMPARATOR
Intervention: Low-dose group (1110 MBq)
Number of subjects: 341